Dr. Reddy's Laboratories Past Earnings Performance
Past criteria checks 2/6
Dr. Reddy's Laboratories has been growing earnings at an average annual rate of 27.1%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 12.1% per year. Dr. Reddy's Laboratories's return on equity is 17.5%, and it has net margins of 17.8%.
Key information
27.1%
Earnings growth rate
27.0%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 12.1% |
Return on equity | 17.5% |
Net Margin | 17.8% |
Next Earnings Update | 23 Jan 2025 |
Recent past performance updates
Recent updates
With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case
Dec 27Are Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Investors Paying Above The Intrinsic Value?
Nov 23Dr. Reddy's Laboratories Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next
Nov 08Insufficient Growth At Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Hampers Share Price
Nov 01Is Dr. Reddy's Laboratories (NSE:DRREDDY) Using Too Much Debt?
Oct 14If EPS Growth Is Important To You, Dr. Reddy's Laboratories (NSE:DRREDDY) Presents An Opportunity
Aug 19Dr. Reddy's Laboratories Limited (NSE:DRREDDY) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
Aug 01The Market Doesn't Like What It Sees From Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Earnings Yet
Jul 30Dr. Reddy's Laboratories (NSE:DRREDDY) Seems To Use Debt Rather Sparingly
Jul 12Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
Jun 23Additional Considerations Required While Assessing Dr. Reddy's Laboratories' (NSE:DRREDDY) Strong Earnings
Jun 20Dr. Reddy's Laboratories (NSE:DRREDDY) Is Paying Out A Dividend Of ₹40.00
May 26Dr. Reddy's Laboratories (NSE:DRREDDY) Will Pay A Dividend Of ₹40.00
May 10With EPS Growth And More, Dr. Reddy's Laboratories (NSE:DRREDDY) Makes An Interesting Case
May 06There Is A Reason Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) Price Is Undemanding
Apr 18Earnings Beat: Dr. Reddy's Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 02Should You Be Adding Dr. Reddy's Laboratories (NSE:DRREDDY) To Your Watchlist Today?
Jan 19Revenue & Expenses Breakdown
How Dr. Reddy's Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 299,867 | 53,332 | 86,402 | 25,906 |
30 Jun 24 | 288,507 | 55,579 | 82,190 | 24,082 |
31 Mar 24 | 279,164 | 55,684 | 77,201 | 22,873 |
31 Dec 23 | 271,302 | 52,206 | 74,717 | 21,362 |
30 Sep 23 | 266,854 | 50,888 | 72,470 | 20,618 |
30 Jun 23 | 261,109 | 47,216 | 70,235 | 20,040 |
31 Mar 23 | 245,879 | 45,067 | 68,026 | 19,381 |
31 Dec 22 | 237,279 | 36,350 | 65,708 | 18,341 |
30 Sep 22 | 222,776 | 30,944 | 63,138 | 17,679 |
30 Jun 22 | 217,351 | 29,736 | 62,529 | 17,273 |
31 Mar 22 | 214,391 | 23,568 | 62,081 | 17,482 |
31 Dec 21 | 207,307 | 26,317 | 60,717 | 17,250 |
30 Sep 21 | 203,406 | 19,450 | 59,693 | 17,199 |
30 Jun 21 | 194,741 | 17,153 | 56,849 | 17,095 |
31 Mar 21 | 189,722 | 17,238 | 54,650 | 16,541 |
31 Dec 20 | 186,756 | 21,256 | 52,457 | 16,637 |
30 Sep 20 | 181,298 | 15,361 | 50,740 | 16,478 |
30 Jun 20 | 180,340 | 18,663 | 50,850 | 15,781 |
31 Mar 20 | 174,600 | 19,498 | 50,129 | 15,410 |
31 Dec 19 | 170,448 | 16,200 | 50,246 | 14,882 |
30 Sep 19 | 165,110 | 26,749 | 49,484 | 14,601 |
30 Jun 19 | 155,079 | 20,862 | 48,639 | 15,059 |
31 Mar 19 | 153,851 | 18,795 | 48,680 | 15,607 |
31 Dec 18 | 149,034 | 17,473 | 48,400 | 16,293 |
30 Sep 18 | 148,594 | 15,965 | 48,540 | 17,292 |
30 Jun 18 | 145,903 | 13,776 | 47,200 | 17,347 |
31 Mar 18 | 141,855 | 9,806 | 46,857 | 18,265 |
31 Dec 17 | 141,827 | 9,909 | 45,370 | 18,458 |
30 Sep 17 | 140,588 | 11,266 | 44,663 | 18,747 |
30 Jun 17 | 140,907 | 11,367 | 45,405 | 19,786 |
31 Mar 17 | 139,870 | 12,039 | 46,300 | 19,513 |
31 Dec 16 | 141,269 | 9,660 | 46,961 | 19,718 |
30 Sep 16 | 144,127 | 10,751 | 47,659 | 18,857 |
30 Jun 16 | 148,410 | 15,019 | 46,943 | 18,116 |
31 Mar 16 | 153,866 | 20,013 | 45,641 | 17,701 |
31 Dec 15 | 155,850 | 24,456 | 44,152 | 18,100 |
30 Sep 15 | 154,602 | 24,409 | 43,264 | 18,321 |
30 Jun 15 | 150,592 | 22,932 | 42,879 | 17,961 |
31 Mar 15 | 147,360 | 22,179 | 42,076 | 17,329 |
31 Dec 14 | 143,474 | 21,806 | 42,810 | 16,289 |
30 Sep 14 | 140,380 | 22,247 | 42,102 | 14,952 |
30 Jun 14 | 138,076 | 23,409 | 41,165 | 13,847 |
31 Mar 14 | 132,170 | 21,515 | 38,783 | 12,402 |
Quality Earnings: DRREDDY has high quality earnings.
Growing Profit Margin: DRREDDY's current net profit margins (17.8%) are lower than last year (19.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DRREDDY's earnings have grown significantly by 27.1% per year over the past 5 years.
Accelerating Growth: DRREDDY's earnings growth over the past year (4.8%) is below its 5-year average (27.1% per year).
Earnings vs Industry: DRREDDY earnings growth over the past year (4.8%) did not outperform the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: DRREDDY's Return on Equity (17.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/10 18:55 |
End of Day Share Price | 2025/01/10 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dr. Reddy's Laboratories Limited is covered by 81 analysts. 36 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Nitin Bhasin | Ambit Capital |
Prashant Nair | Ambit Capital |
null null | Anand Rathi Shares and Stock Brokers Limited |